Stock Events

Stock Events

Innoviva 

€20.2
0
-€0.2-0.98% Today

Statistics

Day High
20.4
Day Low
20.2
52W High
20.6
52W Low
14.1
Volume
0
Avg. Volume
3
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2025
Next
0.33
0.77
1.2
1.64
Expected EPS
0.3305523
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HVE.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline, partner in respiratory products, also competes in overlapping market segments.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca competes in the respiratory and biopharmaceutical market, similar to Innoviva's interests.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals is involved in treating cystic fibrosis, a respiratory condition, thus competing with Innoviva.
Biogen
BIIB
Mkt Cap25.38B
Biogen competes in the biopharmaceutical space with a focus on innovative therapies, overlapping with Innoviva's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals competes in the biopharmaceutical field, focusing on innovative drug development like Innoviva.
AMGEN
AMGN
Mkt Cap189.22B
Amgen operates in the biopharmaceutical sector, focusing on innovative treatments, competing with Innoviva.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences competes in the biopharmaceutical market with a focus on innovation and research, similar to Innoviva.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie operates in the biopharmaceutical field, with a focus on research-based pharmaceuticals, competing with Innoviva.
Merck
MRK
Mkt Cap300.2B
Merck & Co. competes in the pharmaceutical and biopharmaceutical sectors, focusing on innovative therapies.
Pfizer
PFE
Mkt Cap153.13B
Pfizer competes across various therapeutic areas, including respiratory diseases, overlapping with Innoviva's market interests.

About

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Show more...
CEO
Mr. Pavel Raifeld C.F.A.
Employees
127
Country
United States
ISIN
US45781M1018

Listings

MU
DE
HVE.MU
STU
DE
HVE.STU
XNAS
US
INVA
F
DE
HVE.F

0 Comments

Share your thoughts

FAQ

What is Innoviva stock price today?▼
The current price of HVE.STU is €20.2 EUR — it has decreased by -0.98% in the past 24 hours. Watch Innoviva stock price performance more closely on the chart.
What is Innoviva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Innoviva stocks are traded under the ticker HVE.STU.
Is Innoviva stock price growing?▼
HVE.STU stock has fallen by -0% compared to the previous week, the month change is a +6.32% rise, over the last year Innoviva has showed a +27.04% increase.
When is the next Innoviva earnings date?▼
Innoviva is going to release the next earnings report on May 13, 2026.
What were Innoviva earnings last quarter?▼
HVE.STU earnings for the last quarter are 1.64 EUR per share, whereas the estimation was 0.47 EUR resulting in a +252.11% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Innoviva have?▼
As of April 15, 2026, the company has 127 employees.
In which sector is Innoviva located?▼
Innoviva operates in the Health & Wellness sector.
When did Innoviva complete a stock split?▼
Innoviva has not had any recent stock splits.
Where is Innoviva headquartered?▼
Innoviva is headquartered in Burlingame, United States.